- Home
- CVKD vs ASBP Comparison
CVKD vs ASBP Comparison
Compare CVKD & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- ASBP
- Stock Information
- Founded
- CVKD 2022
- ASBP 2021
- Country
- CVKD United States
- ASBP United States
- Employees
- CVKD N/A
- ASBP N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- ASBP Health Care
- Exchange
- CVKD Nasdaq
- ASBP Nasdaq
- Market Cap
- CVKD 29.5M
- ASBP 26.6M
- IPO Year
- CVKD 2023
- ASBP N/A
- Fundamental
- Price
- CVKD $12.64
- ASBP $0.45
- Analyst Decision
- CVKD Strong Buy
- ASBP
- Analyst Count
- CVKD 1
- ASBP 0
- Target Price
- CVKD $32.00
- ASBP N/A
- AVG Volume (30 Days)
- CVKD 24.4K
- ASBP 4.7M
- Earning Date
- CVKD 11-06-2025
- ASBP 08-13-2025
- Dividend Yield
- CVKD N/A
- ASBP N/A
- EPS Growth
- CVKD N/A
- ASBP N/A
- EPS
- CVKD N/A
- ASBP N/A
- Revenue
- CVKD N/A
- ASBP N/A
- Revenue This Year
- CVKD N/A
- ASBP N/A
- Revenue Next Year
- CVKD N/A
- ASBP N/A
- P/E Ratio
- CVKD N/A
- ASBP N/A
- Revenue Growth
- CVKD N/A
- ASBP N/A
- 52 Week Low
- CVKD $8.74
- ASBP $0.22
- 52 Week High
- CVKD $22.90
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- CVKD 48.59
- ASBP 47.54
- Support Level
- CVKD $13.12
- ASBP $0.41
- Resistance Level
- CVKD $13.69
- ASBP $0.47
- Average True Range (ATR)
- CVKD 0.59
- ASBP 0.05
- MACD
- CVKD -0.06
- ASBP -0.02
- Stochastic Oscillator
- CVKD 21.08
- ASBP 35.56
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.